Sec Form 4 Filing - ATIEH MICHAEL G @ Oyster Point Pharma, Inc. - 2020-10-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ATIEH MICHAEL G 2. Issuer Name and Ticker or Trading Symbol Oyster Point Pharma, Inc. [ OYST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109 3. Date of Earliest Transaction (MM/DD/YY) 10/08/2020 (Street) PRINCETON, NJ08540 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock ( 1 ) 10/08/2020 A 15,295 ( 2 ) A $ 0 15,295 D Common Stock ( 1 ) 10/08/2020 A 4,400 ( 3 ) A $ 0 19,695 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ATIEH MICHAEL G C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON, NJ08540 X	Signatures /s/ Shashi Khiani, Attorney-in-Fact 10/13/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This security represents restricted stock units (the "RSUs"). Each RSU represents a contingent right to received one share of common stock of the Issuer. ( 2 )1/3 of the RSUs will vest in three equal annual installments, with 1/3 vesting on the one (1) year anniversary of October 8, 2020, and one-third (1/3) of the RSUs vesting annually thereafter on October 8, subject to the Reporting Person continuing to be a service provider pursuant to the terms of the Issuer's 2019 Equity Incentive Plan through each such date. ( 3 )1/8 of the RSUs will vest in eight equal monthly installments beginning on the first month following the grant date on the same day of the month until the Company's Annual Meeting of Stockholders to be held in 2021; provided, however, if all of such RSUs are not fully vested at the Company's next Annual Meeting of Stockholders, any such remaining RSUs will vest on such date, in each case, subject to the Reporting Person continuing to be a service provider pursuant to the terms of the Issuer's 2019 Equity Incentive Plan through each such date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.